SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Kosan BioSciences -- KOSN
An SI Board Since May 2001
Posts SubjectMarks Bans Symbol
933 40 0 KOSN
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
533J Clin Oncol. 2005 Apr 20;23(12):2726-34. Phase II Clinical Trial of Ixabepiloscaram(o)uche-4/20/2005
532Kosan Presents Preclinical Data at AACR Indicating Clinical Potential of KOS-158scaram(o)uche-4/18/2005
531ASCO...... Sunday, 5/15/2005, 8:00 - 12:00pm Phase 1 and pharmacokinetic (PK) sscaram(o)uche-4/15/2005
530Great read. Thanks! (eom)scaram(o)uche-4/8/2005
529A new Geldanamycin competitor -http://www.forbes.com/forbes/2005/0425/074_print.gfp927z-4/7/2005
528Just keep turning over rocks to find more undervalued stuff to make money. Hopimopgcw-4/7/2005
527During lunch, I listened to an April 5th presentation at CIBC. I won't go insjemmeri-4/7/2005
526Message 21162964 Doing my best with this rejected and maligned pup! PS..Rick..zeta1961-4/7/2005
525You actively go out and bring in stuff. Before and after Tysabri, you are williscaram(o)uche-4/7/2005
524<i>silent faithful ones who would rather suffer than make a case for theirzeta1961-4/7/2005
523I was wondering... the company comes out with a release saying that they'scaram(o)uche-4/7/2005
522Roche and Kosan Breast Cancer Phase II Trial to Proceed Tuesday April 5, 7:30 amscaram(o)uche-4/5/2005
521[Geldanamycin + Bortezomib versus leukemia] >>Mol Cancer Res. 2005 Mar;3(tuck-3/31/2005
520don't know about you, but I could not resist to add to the position at $4 hemopgcw-3/30/2005
519>> J Clin Oncol. 2005 Mar 20;23(9):1885-93. Phase I and pharmacologic sttuck-3/30/2005
518[In vivo antitumor efficacy of 17-DMAG] >>Cancer Chemother Pharmacol. 200tuck-3/27/2005
517[Total synthesis of EPO D -- Protarga] >>Bioorg Chem. 2005 Apr;33(2):116-tuck-3/25/2005
516You've been away a long time!tom pope-3/7/2005
515"Hidden Gem" Yahoo Finance 1y Target Est: 15.38 151.88M Market Cap, 6Andrew W. Jewell-3/7/2005
514From today's Fiscal '04' Financial Release: (notice the projected inExtra Pale-2/24/2005
513[Phase I Trial of 17-AAG in Patients With Advanced Cancer] Journal of Clinical tuck-2/18/2005
512Kosan Initiates Phase II Trial of KOS-862 (Epothilone D) for Prostate Cancer 14 FiloF-2/14/2005
511Kosan Names Pieter Timmermans Senior Vice President, Preclinical Development Thukeokalani'nui-2/3/2005
510[17-AAG or 17-DMAG against gynecologic cancers] >>Gynecol Oncol. 2005 Febtuck-1/24/2005
509>>HAYWARD, Calif., Dec. 8 /PRNewswire-FirstCall/ -- Kosan Biosciences Incotuck-1/5/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News